Kai Yang

10PUBLICATIONS
26CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsBiomolecular modelling and designProteins and peptidesMedical infection agents (incl. prions)Medical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 01, 2026
High-Throughput Screening Identifies Covalent Inhibitors with Unique Chemistry and Binding Modes for SARS-CoV‑2 Main Protease.

|Apr 14, 2026
Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad.

Sandeep Atla, Veerabhadra Vulupala, Yugendar R Alugubelli

|Jun 19, 2024
SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme.

Lauren R Blankenship, Kai S Yang, Veerabhadra R Vulupala

|Aug 10, 2023
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.

Zhi Zachary Geng, Sandeep Atla, Namir Shaabani

|Jan 11, 2023
A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease.

Kai S Yang, Lauren R Blankenship, Syuan-Ting Alex Kuo

|Nov 16, 2022
Phage-assisted, active site-directed ligand evolution of a potent and selective histone deacetylase 8 inhibitor.

Jared S Morse, Yan J Sheng, Joshua Trae Hampton

Pageof 2

Frequent Collaborators

9 joint publications

Wenshe Ray Liu

8 joint publications

Shiqing Xu

3 joint publications

Benjamin W Neuman

2 joint publications

Satyanarayana Nyalata